In efforts to develop an effective therapy for such Keap1/Nrf2 pathway‐activated cancers, several small‐molecule compounds have been reported as Keap1/Nrf2 pathway inhibitors.27, 28, 29, 30, 31, 32, 33 These compounds have shown enhanced sensitivity to other anti‐cancer drugs and inhibited tumor growth in Keap1/Nrf2 pathway‐activated cancer models both in vitro and in vivo. This evidence concerns the gene KEAP1 and cancer.